February 22, 2021August 24, 2022
Enhertu Approved in UK for Inoperable, Advanced Breast Cancer
News
Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic ... Read more
February 18, 2021February 18, 2021
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC
News
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in ... Read more
February 15, 2021February 15, 2021
Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer
News
Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously ... Read more
February 11, 2021February 11, 2021
Trial Testing AL101 in TNBC Doses First Patient
News
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy ... Read more
February 8, 2021February 8, 2021
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
News
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative ... Read more
February 4, 2021February 4, 2021
Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors
News
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide ... Read more
February 1, 2021February 1, 2021
US Study Enrolling Women to Help Determine Best Screening Practices
News
A national study is seeking women in the U.S. to help determine the safest and best way to screen for ... Read more
January 28, 2021January 28, 2021
Nonprofit Highlights Importance of Global Teamwork for World Cancer Day
News
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation ... Read more
January 25, 2021January 25, 2021
Enhertu Approved in EU for Inoperable, Advanced Breast Cancer
News
The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer ... Read more
January 21, 2021January 21, 2021
Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA
News
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and ... Read more
January 18, 2021January 18, 2021
Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors
News
Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The ... Read more
January 14, 2021January 14, 2021
Genetic Test for Advanced Breast Cancer Launched in EU
News
Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic ... Read more

October 1, 2020October 1, 2020

Activities Abound for Breast Cancer Awareness Month

News

October is Breast Cancer Awareness Month, set aside annually to bring attention to the disorder and the community’s needs. From sharing photographs and educational resources, to hosting virtual fundraisers and wearing ... Read more

September 28, 2020September 28, 2020

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

News

When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast cancer ... Read more

September 24, 2020September 24, 2020

Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant

News

The first participant has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of GDC-9545 in combination with palbociclib as an investigational treatment for postmenopausal women with estrogen receptor ... Read more

September 21, 2020September 21, 2020

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

News

Patient dosing has begun in Zion Pharma‘s Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast ... Read more

September 17, 2020September 17, 2020

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

News

TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose in ... Read more

September 14, 2020September 14, 2020

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

News

The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte‘s immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, as ... Read more

September 10, 2020September 10, 2020

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

News

Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free survival ... Read more

September 3, 2020September 3, 2020

FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) is reviewing a new drug application from Athenex seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast ... Read more

August 31, 2020August 31, 2020

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

News

The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer (TNBC). ... Read more

August 27, 2020August 27, 2020

Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial

News

Tecentriq (atezolizumab) combined with chemotherapy failed to meet its primary endpoint of progression-free survival — the length of time during and after therapy in which the patient’s disease does not get ... Read more

August 24, 2020August 24, 2020

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

News

The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative ... Read more

August 17, 2020August 17, 2020

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

News

The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who received ... Read more

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Trial Testing AL101 in TNBC Doses First Patient

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

US Study Enrolling Women to Help Determine Best Screening Practices

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Genetic Test for Advanced Breast Cancer Launched in EU